Blackstone Life Sciences has agreed to acquire Anthos Therapeutics, a clinical-stage biopharmaceutical company developing innovative therapies for cardiometabolic diseases, for $3.1 billion. The deal gives Blackstone exclusive global rights to develop, manufacture and commercialize abelacimab, an investigational monoclonal antibody targeting Factor XI.
Abelacimab received Fast Track Designation from the FDA in July 2022 for the treatment of thrombosis associated with cancer and prevention of stroke and systemic embolism in patients with atrial fibrillation. The company has been working on developing abelacimab as a potential breakthrough treatment for these conditions.
The acquisition is expected to bring significant value to both Blackstone and Anthos Therapeutics, with the potential for improved patient outcomes and increased revenue growth. However, the deal also comes with risks, including the possibility that various conditions may not be satisfied or waived, which could impact the transaction’s success.
Blackstone Life Sciences has a strong track record of investing in innovative life sciences companies, and this acquisition is expected to further enhance its portfolio. The company currently has $12 billion in assets under management and has invested across various stages of product development.
The deal is subject to regulatory approval and other customary conditions. With the support of Blackstone’s expertise and resources, Anthos Therapeutics aims to accelerate the development and commercialization of abelacimab, bringing it closer to its potential as a life-changing treatment for patients with cardiometabolic diseases.
Source: https://www.blackstone.com/news/press/blackstone-life-sciences-and-anthos-therapeutics-announce-agreement-for-anthos-to-be-acquired-by-novartis-for-up-to-3-1-billion